ACUTE REVERSIBLE NEUROLOGICAL DEFICIT FOLLOWING INTRATHECAL CHEMOTHERAPY

被引：8

作者：

DUNKELMAN, H ^{[1
]}

EARL, HM ^{[1
]}

TWELVES, C ^{[1
]}

机构：

[1] UNIV COLL HOSP LONDON,DEPT RADIOTHERAPY & ONCOL,LONDON WC1E 6AU,ENGLAND

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1991年 / 27卷 / 04期

关键词：

D O I：

10.1007/BF00685121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report on two patients with non-Hodgkin's lymphoma (NHL) who developed reversible, short-lived neurological deficit following intrathecal (i.t.) chemotherapy. One patient received i.t. methotrexate for treatment of meningeal disease, and the other received i.t. methotrexate with cytosine arabinoside (ara-C) and hydrocortisone as central nervous system (CNS) prophylaxis. Although transient paresis following i.t. chemotherapy has previously been reported, it has been attributed to the preservatives contained in the diluents. Our two patients, however, received preservative-free solutions.

引用

页码：329 / 330

页数：2

共 20 条

[1]

BACK EH, 1969, LANCET, V2, P1005

[2]

BAGSHAWE KD, 1969, LANCET, V2, P1258

[3] NEUROTOXICITY AND ELEVATED CEREBROSPINAL-FLUID METHOTREXATE CONCENTRATION IN MENINGEAL LEUKEMIA [J].

BLEYER, WA ;

DRAKE, JC ;

CHABNER, BA .

NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (15) :770-773

[4]

BREUER AC, 1977, CANCER, V40, P2817, DOI 10.1002/1097-0142(197712)40:6<2817::AID-CNCR2820400611>3.0.CO

[5]

2-V

[6]

CLARK AW, 1982, CANCER, V50, P42, DOI 10.1002/1097-0142(19820701)50:1<42::AID-CNCR2820500109>3.0.CO

[7]

2-M

[8]

GAGLIANO RG, 1976, CANCER, V37, P1663, DOI 10.1002/1097-0142(197604)37:4<1663::AID-CNCR2820370408>3.0.CO

[9]

2-7

[10] PARAPARESIS FOLLOWING INTRATHECAL CHEMOTHERAPY [J].

HAHN, AF ;

FEASBY, TE ;

GILBERT, JJ .

NEUROLOGY, 1983, 33 (08) :1032-1038

← 1 2 →